Table 3.
Correlation of clinicopathologic characteristics and the twelve-gene signature in HCC
| Characteristics | TCGA-LIHC | GSE14520 | ||||
|---|---|---|---|---|---|---|
| Low risk N = 176 |
High risk N = 57 |
P | Low risk N = 94 |
High risk N = 121 |
P | |
| Follow-up time (mouths) | 31.49 ± 25.24 | 21.85 ± 18.99 | 0.009 | 47.51 ± 18.72 | 34.36 ± 22.00 | 0.000 |
| Risk score | 1.23 ± 0.35 | 2.05 ± 0.25 | 0.000 | 0.54 ± 0.22 | 1.29 ± 0.29 | 0.000 |
| Age (years) | 0.565 | 0.282 | ||||
| ≤ 60 | 88 (50.0%) | 26 (45.6%) | 73 (77.7%) | 101 (83.5%) | ||
| > 60 | 88 (50.0%) | 31 (54.4%) | 21 (22.3%) | 20 (16.5%) | ||
| Sex | 0.008 | 0.595 | ||||
| Female | 50 (28.4%) | 27 (47.4%) | 14 (14.9%) | 15 (12.4%) | ||
| Male | 126 (71.6%) | 30 (52.6%) | 80 (85.1%) | 106 (87.6%) | ||
| BMI (kg/m2) | 0.664 | |||||
| < 25 | 93 (52.8%) | 32 (56.1%) | – | – | ||
| ≥ 25 | 83 (47.2%) | 25 (43.9%) | – | – | ||
| G stage | 0.000 | |||||
| G1 + G2 | 111 (63.1%) | 17 (29.8%) | – | – | ||
| G3 + G4 | 65 (36.9%) | 40 (70.2%) | – | – | ||
| Residual tumor | 0.905 | |||||
| R0 | 166 (94.3%) | 54 (94.7%) | – | – | ||
| Non-R0 | 10 (5.7%) | 3 (5.3%) | – | – | ||
| AJCC stage | 0.089 | 0.006 | ||||
| I + II | 150 (85.2%) | 43 (75.4%) | 81 (86.2%) | 85 (70.2%) | ||
| III + IV | 26 (14.8%) | 14 (24.6%) | 13 (13.8%) | 36 (29.8%) | ||
| Vascular invasion | 0.000 | |||||
| No | 129 (73.3%) | 23 (40.4%) | – | – | ||
| Yes | 47 (26.47%) | 34 (59.6%) | – | – | ||
| AFP (ng/ml) | 0.002 | 0.001 | ||||
| < 300 | 144 (81.8%) | 35 (61.4%) | 64 (68.1%) | 54 (44.6%) | ||
| ≥ 300 | 32 (18.2%) | 22 (38.6%) | 30 (31.9%) | 67 (55.4%) | ||
| Multinodular | 0.214 | |||||
| No | – | – | 78 (83.0%) | 92 (76.0%) | ||
| Yes | – | – | 16 (17.0%) | 29 (24.0%) | ||
| Cirrhosis | 0.575 | |||||
| No | – | – | 9 (9.6%) | 9 (7.4%) | ||
| Yes | – | – | 85 (90.4%) | 112 (92.6%) | ||